Medication non-compliance: When hard science meets soft science

International Congress Series

Volumn 1220, Issue C, 2001, Pages 125-133

  Levy, Gerhard ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Clinical pharmacology; Package insert; Pharmacodynamics; Pharmacokinetics; Simulation

Indexed keywords

EID: 84967225361     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0531-5131(01)00292-8     Document Type: Article

References (16)

1. Gibaldi, M., Failure to comply: a therapeutic dilemma and the bane of clinical trials. J. Clin. Pharmacol. 36 (1996), 674–682.
2. Cramer, J.A., Spilker, B., (eds.) Patient Compliance in Medical Practice and Clinical Trials, 1991, Raven Press, New York, 301–322.
3. Urquhart, J., Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. Clin. Pharmacol. Ther. 67 (2000), 331–334.
4. Jacobs, J., Goldstein, A.G., Kelly, M.E., Bloom, B.S., NSAID dosing schedule and compliance. Drug Intell. Clin. Pharm. 22 (1988), 727–728.
5. Paes, A.H.P., Bakker, A., Soe-Agnie, C.J., Impact of dosage frequency on patient compliance. Diabetes Care 20 (1997), 1512–1517.
6. Levy, G., A pharmacokinetic perspective on medicament noncompliance. Clin. Pharmacol. Ther. 54 (1993), 242–244.
7. Greenberg, R.N., Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 6 (1984), 592–599.
8. Alfredsson, L., Bergman, U., Eriksson, R., Gronskog, K., Norell, S., Schwartz, E., Wiholm, B.E., Theophyllines three times daily—when are the doses actually taken? Pharmacokinetic ideals versus clinical practice. Eur. J. Respir. Dis. 63 (1982), 234–238.
9. Spyker, D.A., Harvey, E.D., Harvey, B.E., Harvey, A.M., Rumack, B.H., Peck, C.C., Atkinson, A.J., Woosley, R.L., Abernethy, D.R., Cantilena, L.R., Assessment and reporting of clinical pharmacology information in drug labeling. Clin. Pharmacol. Ther. 67 (2000), 196–200.
10. Nagashima, R., O'Reilly, R.A., Levy, G., Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin. Pharmacol. Ther. 10 (1969), 22–35.
11. Jusko, W.J., Ko, H.C., Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin. Pharmacol. Ther. 56 (1994), 406–419.
12. Sharma, A., Jusko, W.J., Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br. J. Clin. Pharmacol. 45 (1998), 229–239.
13. Urquhart, J., Variable patient compliance as a source of variability in drug response. Tucker, Gt., (eds.) Variability in Human Drug Response, 1999, Elsevier Science, 189–204.
14. Sheiner, L.B., Stanski, D.R., Vozeh, S., Miller, R.D., Ham, J., Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25 (1979), 358–371.
15. Nony, P., Cucherat, M., Boissel, J.P., Revisiting the effect compartment through timing errors in drug administration. TIPS 19 (1998), 49–54.
16. Chiquette, E., Amato, M.G., Bussey, H.I., Comparison of an anticoagulation clinic with usual medical care. Arch. Intern. Med. 158 (1998), 1641–1647.